Faculty profile

Devin Schellenberg

ResearcherRadiation OncologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Devin Schellenberg

Researcher

Radiation Oncology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
24 publications in the last five years, latest in 2026.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

2,004

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Clinical Trials Metastases Oligometastases Radiation Oncology Stereotactic Ablative Radiotherapy

Latest papers

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
Multi-lead Monitoring to Deduce Translations and Rotations of the Heart Through Respiration and Its Geometric Implications for Motion Management in Cardiac Radioablation.
International journal of radiation oncology, biology, physics · 2026
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
International journal of radiation oncology, biology, physics · 2026

All 46 publications

Latest funding

Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy
CIHR · 2022 · Principal investigator
$9,980
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
CIHR · 2019 · Co-investigator
$699,380

All 2 grants and awards

46 publications.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Olson R, Liu M, Bergman A, Mou B, Abraham H, Leclerc C, Carolan H, Schellenberg D, Jiang W, Alexander A, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Gautam D, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S, Baker S

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026

DOI: 10.1016/j.radonc.2026.111532 PMID: 42140754

Multi-lead Monitoring to Deduce Translations and Rotations of the Heart Through Respiration and Its Geometric Implications for Motion Management in Cardiac Radioablation.

Marshall J, Karan T, Bergman A, Schellenberg D, Deyell MW, Thomas S

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2026.03.015 PMID: 41850495

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.03.079 PMID: 40216089

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, Mou B, Liu M, Hsu F, Berrang T, Atrchian S, Bergman A, Chng N, Matthews Q, Chang JS, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.01.031 PMID: 39923903

The role of abdominal compression in the reduction of respiratory motion for cardiac radioablation.

Marshall J, Bergman A, Karan T, Deyell MW, Schellenberg D, Thomas S

Journal of applied clinical medical physics2026

DOI: 10.1002/acm2.70561 PMID: 41904693

Margins to account for cardiac and respiratory motion in cardiac radioablation.

Marshall J, Poon J, Bergman A, Karan T, Deyell MW, Schellenberg D, Thompson RB, Thomas S

Medical physics2025

DOI: 10.1002/mp.70041 PMID: 41024249

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Willmann J, Baker S, Chen H, Dee EC, Vlaskou Badra E, Christ SM, Mayinger M, Ahmadsei M, Adilovic S, Das S, Lechner L, Liu W, Liu M, Mou B, Berrang T, Schellenberg D, Tyldesley S, Erler D, Iyengar P, Redmond K, Ricardi U, Guckenberger M, Sahgal A, Olson R, Andratschke N

European journal of cancer (Oxford, England : 1990)2025

DOI: 10.1016/j.ejca.2025.115737 PMID: 40876085

Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System.

McDermott RL, Dunne EM, Ma LIJ, Bergman AM, Camborde MA, Karan T, Mestrovic A, Carpentier EE, Liu MCC, Schellenberg D, Ma RMK

Cancers2025

DOI: 10.3390/cancers17172926 PMID: 40941023

Toward the Use of Implanted Cardiac Leads or the Diaphragm for Active Respiratory Motion Management in Stereotactic Arrhythmia Radioablation.

Marshall J, Bergman A, Karan T, Deyell MW, Schellenberg D, Thomas S

International journal of radiation oncology, biology, physics2025

DOI: 10.1016/j.ijrobp.2025.02.035 PMID: 40043856

Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis.

Abrina JP, Baker S, Cruz-Lim EM, Chng N, Ye A, Rathod S, Caon J, Schellenberg D, Liu M, Mou B

Practical radiation oncology2025

DOI: 10.1016/j.prro.2024.07.012 PMID: 39303778

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Cancer Dear Professor Schellenberg, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Devin Schellenberg

Research

Latest papers

Latest funding

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Multi-lead Monitoring to Deduce Translations and Rotations of the Heart Through Respiration and Its Geometric Implications for Motion Management in Cardiac Radioablation.

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

The role of abdominal compression in the reduction of respiratory motion for cardiac radioablation.

Margins to account for cardiac and respiratory motion in cardiac radioablation.

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System.

Toward the Use of Implanted Cardiac Leads or the Diaphragm for Active Respiratory Motion Management in Stereotactic Arrhythmia Radioablation.

Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis.

Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

Frequent collaborators

Robert Olson

Scott Tyldesley

Stewart Gaede

Anand Swaminath

Shahid Ahmed

Alan Nichol

Michael Mckenzie

Alison Allan

Laura Dawson

Meredith Giuliani

Michael Peacock

Glenn Bauman

Janet Papadakos

Andrew Hope

Mira Keyes

George Rodrigues

Arjun Sahgal

Doris Howell